We are live on ! Find out more
ABMD

Abiomed Inc

Delisted

ABMD was delisted on the 21st of December, 2022.

460 hedge funds and large institutions have $10.5B invested in Abiomed Inc in 2020 Q2 according to their latest regulatory filings, with 90 funds opening new positions, 141 increasing their positions, 165 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 90 | Existing positions closed: 40

68% more capital invested

Capital invested by funds: $6.25B → $10.5B (+$4.23B)

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

12% more funds holding

Funds holding: 412460 (+48)

13% less call options, than puts

Call options by funds: $154M | Put options by funds: $177M

15% less repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 165

Holders
460
Holders Change
+48
Holders Change %
+11.65%
% of All Funds
9.41%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.1%
New
90
Increased
141
Reduced
165
Closed
40
Calls
$154M
Puts
$177M
Net Calls
-$22.9M
Net Calls Change
+$54M

ABMD Hedge Fund Activity: Q2 2020 in Review

460 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Abiomed Inc (ABMD) for Q2 2020, worth a combined $10.5B — up 68% from $6.25B a quarter earlier.

Buyers outnumbered sellers: 90 funds opened new ABMD positions and 40 closed out — a net gain of 50 holders — while 141 added to existing stakes and 165 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $49.8M. The largest seller was Wellington Management Group, cutting an estimated $115M.

  • 460 institutional investors held Abiomed Inc (ABMD) as of Q2 2020, up from 412 in Q1 2020.
  • Funds reported $10.5B of Abiomed Inc stock for Q2 2020, up 68% quarter-over-quarter.
  • 90 funds opened new Abiomed Inc positions in Q2 2020 and 40 closed out, a net change of +50 holders.
  • The largest Abiomed Inc buyer in Q2 2020 was JP Morgan Chase, an estimated $49.8M added.
  • The largest Abiomed Inc seller in Q2 2020 was Wellington Management Group, an estimated $115M sold.

Based on aggregated 13F filings for Q2 2020.